Overview

Aging Mammary Stem Cells and Breast Cancer Prevention

Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
To examine whether rapamycin can reduce malignant markers and aberrant mammary stem/progenitor cells (MaSCs) number in surgical specimens
Phase:
Phase 2
Details
Lead Sponsor:
LuZhe Sun
The University of Texas Health Science Center at San Antonio
Collaborator:
National Cancer Institute (NCI)
Treatments:
Everolimus
Sirolimus